D. E. Shaw & Co., Inc. Day One Biopharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 224,340 shares of DAWN stock, worth $3.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

224,340

Previous 224,219 0.05%

Holding current value

$3.46 Million

Previous $3.7 Million 16.55%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $1,455 - $2,140	121 Added 0.05%	224,340 $3.09 Million
Q1 2024 May 15, 2024	BUY	$13.56 - $17.46 $389,578 - $501,625	28,730 Added 14.7%	224,219 $3.7 Million
Q4 2023 Feb 14, 2024	SELL	$9.68 - $15.37 $7,153 - $11,358	-739 Reduced 0.38%	195,489 $2.85 Million
Q3 2023 Nov 14, 2023	SELL	$11.22 - $14.86 $192,849 - $255,413	-17,188 Reduced 8.05%	196,228 $2.41 Million
Q2 2023 Aug 14, 2023	SELL	$11.74 - $14.47 $2.48 Million - $3.05 Million	-210,963 Reduced 49.71%	213,416 $2.55 Million
Q1 2023 May 15, 2023	SELL	$12.75 - $23.41 $2.26 Million - $4.14 Million	-176,943 Reduced 29.43%	424,379 $5.67 Million
Q4 2022 Feb 14, 2023	BUY	$18.77 - $22.0 $641,445 - $751,828	34,174 Added 6.03%	601,322 $12.9 Million
Q3 2022 Nov 14, 2022	BUY	$16.44 - $26.57 $7.05 Million - $11.4 Million	428,830 Added 310.03%	567,148 $11.4 Million
Q2 2022 Aug 15, 2022	BUY	$5.72 - $17.9 $791,178 - $2.48 Million	138,318 New	138,318 $2.48 Million
Q1 2022 May 16, 2022	SELL	$9.12 - $17.47 $122,244 - $234,167	-13,404 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.65 - $26.33 $209,772 - $352,927	13,404 New	13,404 $226,000

Others Institutions Holding DAWN

# of Institutions

167

Shares Held

72.1M

Call Options Held

163K

Put Options Held

183K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $1.13B
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account